

ASX RELEASE | OSTEOPORE LIMITED

APPOINTMENT OF JOINT COMPANY SECRETARY

25 January 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenue-generating manufacturer and distributor of regenerative implants that empower natural tissue regeneration, is pleased to advise the appointment of Mrs Kellie Davis as joint Company Secretary, effective 26 January 2023.

Mrs Davis has over 20 years’ experience in accounting and ASX compliance. Beginning her career in Audit with Ernst & Young, she worked for as a Financial Accountant and provided company secretarial services for a number of junior listed ASX companies. Mrs Davis has a Bachelor of Commerce (Accounting and Finance) Degree and is a Chartered Accountants Australia & New Zealand member.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.